Abbmira Therapeutics activates the immune system of cancer patients to fight tumors. Our small molecule compounds are designed to target and activate a specific target in native immune cells that are critical to fight cancer. Our proof-of-concept experiments confirm our experimental compounds stops cancer growth in mice and we now optimising our therapeutic approach to bring molecules to the clinic in the next 3 years. Abbmira addresses an huge unmet medical need in a growing market, estimated to reach $169B by 2032. Abbmira's founding teamoffers 50+ years of combined experience in business, pharma, and life sciences.